D-Net

<?xml version="1.0" encoding="UTF-8"?>

<ROW>

    <FIELD name="trust">0.9</FIELD>

    <FIELD name="contactemail">elke.lammertyn@kuleuven.be</FIELD>

    <FIELD name="code">115797</FIELD>

    <FIELD name="keywords" isNull="true"/>

    <FIELD name="oamandatepublications">true</FIELD>

    <FIELD name="dateofcollection">2018-03-09</FIELD>

    <FIELD name="fundingtree">

        <ITEM>&lt;fundingtree&gt;&lt;funder&gt;&lt;id&gt;ec__________::EC&lt;/id&gt;&lt;shortname&gt;EC&lt;/shortname&gt;&lt;name&gt;European Commission&lt;/name&gt;&lt;jurisdiction&gt;EU&lt;/jurisdiction&gt;&lt;/funder&gt;&lt;funding_level_1&gt;&lt;id&gt;ec__________::EC::H2020::IMI2-RIA&lt;/id&gt;&lt;description&gt;Research and Innovation action&lt;/description&gt;&lt;name&gt;IMI2-RIA&lt;/name&gt;&lt;class&gt;ec:h2020toas&lt;/class&gt;&lt;parent&gt;&lt;funding_level_0&gt;&lt;id&gt;ec__________::EC::H2020&lt;/id&gt;&lt;name&gt;H2020&lt;/name&gt;&lt;description&gt;Horizon 2020 Framework Programme&lt;/description&gt;&lt;parent/&gt;&lt;class&gt;ec:h2020fundings&lt;/class&gt;&lt;/funding_level_0&gt;&lt;/parent&gt;&lt;/funding_level_1&gt;&lt;/fundingtree&gt;

        </ITEM>

    </FIELD>

    <FIELD name="ecarticle29_3">false</FIELD>

    <FIELD name="pid">

        <ITEM isNull="true"/>

    </FIELD>

    <FIELD name="title">Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach

        towards understanding and arresting type 1 diabetes – Sofia ref.: 115797

    </FIELD>

    <FIELD name="startdate">2015-11-01</FIELD>

    <FIELD name="totalcost">36563700</FIELD>

    <FIELD name="duration" isNull="true"/>

    <FIELD name="provenanceaction">

        sysimport:crosswalk:entityregistry@@@Harvested@@@dnet:provenanceActions@@@dnet:provenanceActions

    </FIELD>

    <FIELD name="inferenceprovenance" isNull="true"/>

    <FIELD name="ecsc39" isNull="true"/>

    <FIELD name="collectedfromname">CORDA - COmmon Research DAta Warehouse - Horizon 2020</FIELD>

    <FIELD name="inferred">false</FIELD>

    <FIELD name="currency">EUR</FIELD>

    <FIELD name="contactphone" isNull="true"/>

    <FIELD name="projectid">corda__h2020::115797</FIELD>

    <FIELD name="jsonextrainfo">{}</FIELD>

    <FIELD name="summary">Preclinical type 1 diabetes (T1D) research has made important advances in recent years, but

        less progress has been made in translating findings from in vitro and animal models into effective clinical

        interventions. INNODIA aims to achieve a breakthrough in the way in which we study T1D to enable us to move

        closer towards prevention and cure of T1D. To this end, INNODIA joins together the leading European experts from

        the fields of basic and clinical T1D research, four leading pharmaceutical companies with strong expertise in

        the discovery and development of diabetes medicines and the two leading public organizations involved in T1D

        research into one comprehensive collaborative consortium. The clinicians in INNODIA oversee T1D registries and

        have access to large populations of children and adults with T1D and family members at increased risk of

        developing the disease. The basic science researchers are experts in beta-cell pathophysiology, immunology,

        biomarker discovery, bioinformatics, systems biology and clinical trial design. INNODIA will accelerate

        understanding of T1D through coordinated studies of unique clinical samples and translation-oriented preclinical

        models. This should deliver novel biomarkers and interventions for testing in appropriately designed trials, to

        be developed in active collaboration with regulators and patients. INNODIA provides access to unique historical

        biorepositories and will create the Clinical Sample Network, a clinical EU infrastructure to recruit T1D

        subjects at diagnosis and at-risk relatives. These individuals will be deep-phenotyped and will provide

        biosamples, allowing the establishment of a ‘living biobank’ of subjects consented for recall. They will be

        characterized using standardized clinical, genetic and metabolic phenotyping procedures, including prospective,

        longitudinal sample collection to facilitate novel biomarker discovery. Diverse biological samples (blood,

        plasma, serum, urine, stools, etc.) will be collected at

    </FIELD>

    <FIELD name="collectedfromid">openaire____::corda_h2020</FIELD>

    <FIELD name="acronym">INNODIA</FIELD>

    <FIELD name="callidentifier">H2020-JTI-IMI2-2014-01-two-stage</FIELD>

    <FIELD name="subjects">

        <ITEM>Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus

            (T1DM)###ec:h2020topics@@@Horizon 2020

            Topics@@@dnet:subject_classification_typologies@@@dnet:subject_classification_typologies

        </ITEM>

    </FIELD>

    <FIELD name="contactfax" isNull="true"/>

    <FIELD name="fundedamount">17630000</FIELD>

    <FIELD name="optional2">Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM)

    </FIELD>

    <FIELD name="optional1">IMI2-2014-01-01</FIELD>

    <FIELD name="enddate">2022-10-31</FIELD>

    <FIELD name="contracttype" isNull="true"/>

    <FIELD name="websiteurl" isNull="true"/>

    <FIELD name="dateoftransformation">2019-11-19</FIELD>

    <FIELD name="deletedbyinference">false</FIELD>

    <FIELD name="contactfullname">LAMMERTYN, Elke</FIELD>

</ROW>